Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE ...

A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...

Iovance Biotherapeutics Inc. IOVA stock is trading higher on Friday, with no news to justify the movement. Investors should ...

The National Comprehensive Cancer Network (NCCN) published new guidelines for pediatric soft tissue sarcoma (STS), growing the NCCN’s library of guidelines to now cover 91 topics in cancer care. 1 ...

Iovance Biotherapeutics IOVA shares are surging on Tuesday following the announcement of positive early data from a pilot ...

The National Comprehensive Cancer Network ® (NCCN ®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Pediatric Soft Tissue Sarcomas. This is the 7th NCCN ...

The newly-added diseases include skin cancer, mesothelioma, soft-tissue sarcoma and pharynx cancers, putting the total number ...

Amtagvi revenue growth reached 112% year-over-year, and Proleukin generated about 17% of total revenue for 2025, aligning with prior expectations. The company stated, "The impact of gross to net ...